Can the testing be performed on dogs that are currently on therapy?

Current therapy will not affect our AI predictions or immunoprofile results. However, reduction of tumor size caused by therapy may increase the likelihood of service failure due to insufficient cells. In the event of service failure, you will not be billed.

Other Questions

Back to Help Center

Can the test be used on cats and other animals?

At this time, we only offer commercial services to canine lymphoma patients. However, we are conducting research into feline lymphoma so if you would like to submit a sample please sign up here if you are interested in feline services.

How do vets report back the outcomes to feed back into the AI model? Is this something that can be easily done via the Vet portal?

We usually send you an email asking for patient records about 3-6 months after you receive the final ImpriMed report. Once we receive the record, we input the data into the AI Models, it is not yet something that can be submitted on the Vet Portal.

What is included in the ImpriMed Immunoprofile service?

The ImpriMed Immunoprofile service includes both our Flow Cytometry and PARR reports. These comprehensive results can be used to detect the presence of lymphoma or leukemia and determine the disease subtype.

What does PARR tell me about my patient’s specimen?

PARR, which stands for PCR for Antigen Receptor Rearrangements, is used to discriminate between lymphoma/leukemia and reactive/inflammatory conditions when cytology is equivocal. Our canine PARR assay detects the expansion of B-cell cancer clones by amplifying the VJ region of the immunoglobulin heavy chain gene (IgH) and detects the expansion of T-cell cancer clones by amplifying a region in the T-cell receptor gamma chain gene.

What does flow cytometry tell me about my patient’s specimen?

ImpriMed’s flow cytometry report provides comprehensive information about the specimen’s immunophenotype. B-cell and T-cell immunophenotypes are useful in determining lymphoma/leukemia subtype and prognosis. In addition, our panel of ten antigens can also be used in the diagnosis of T-zonal lymphoma, acute leukemia, and other diseases. Antigens levels reported are: CD21, CD79a, CD3, CD4, CD8, CD5, CD45, CD34, CD14, and MHC class II. For more information, see: https://pubmed.ncbi.nlm.nih.gov/26953614/